The 9 top biotech stocks to buy now to get through the coronavirus crisis, according to JPMorgan

• In an April 3 research note, JPMorgan identified nine biotechnology companies they see as the best investment ideas for 2020.
• In past recessions, in 2001 and 2008-2009, the biotech industry outperformed the broader market. This time around, JPMorgan sees smaller biotechs facing a few big risks, such as disruptions to clinical trials and tightening liquidity for the capital markets.
• Here are the bank's top ideas of 2020 in the biotech industry.
• Visit Business Insider's homepage for more stories.

As the coronavirus pandemic roils financial markets, JPMorgan analysts are highlighting the biotechnolgy industry as one space that has outperformed in past recessions.

In 2008-2009, a leading biotech index outperformed by gaining 1% while the broader market dropped 23%. And in the 2001 recession, the analysts state that same biotech index held flat while the S&P 500 dropped 9%.

This time around, biotech does face some heightened risks. Small companies that depend on clinical trials running on time and launching new drugs could face setbacks, because of the coronavirus overwhelming the healthcare system. Those smaller companies are also more likely to need to tap the markets for capital, according to JPMorgan.

Read more: The coronavirus is upending medical research for cancer to heart disease, as dozens of biotechs put clinical trials on hold

With that said, JPMorgan believes biotech's fundamentals "remain largely intact."

"We expect demand for prescription medication to be fairly inelastic for severe indications and anticipate little in the way of commercial interruption due to inventory disruptions," the analysts said in an April 3 research note to investors.

In particular, the biotech analyst team highlighted nine companies they see as the best ideas for 2020. Here are their top choices.